Jounce Therapeutics (NASDAQ:JNCE) is scheduled to post its quarterly earnings results before the market opens on Wednesday, August 7th. Analysts expect Jounce Therapeutics to post earnings of ($0.26) per share for the quarter. Jounce Therapeutics has set its FY 2019 guidance at EPS.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). Jounce Therapeutics had a negative net margin of 41.13% and a negative return on equity of 26.05%. The business had revenue of $10.98 million for the quarter, compared to the consensus estimate of $14.75 million. On average, analysts expect Jounce Therapeutics to post $0 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of JNCE stock traded up $0.06 during mid-day trading on Thursday, reaching $4.85. 4,637 shares of the company’s stock traded hands, compared to its average volume of 268,571. Jounce Therapeutics has a 12 month low of $2.66 and a 12 month high of $8.58. The firm’s 50 day moving average price is $4.57. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.20. The stock has a market cap of $157.61 million, a price-to-earnings ratio of -5.94 and a beta of 3.45.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.